MiR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 384-392

  Liu, Peng ^a   Tang, Hailin ^a   Chen, Bo ^a   He, Zhimin ^b   Deng, Min ^b   Wu, Minqing ^a   Liu, Xiaoping ^a   Yang, Lu ^a   Ye, Feng ^a   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

MiR 26a; MTDH; Triple negative breast cancer

Indexed keywords

CELL PROTEIN; MESSENGER RNA; METADHERIN; MICRORNA 26A; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; MICRORNA; MIRN26A MICRORNA, HUMAN; MTDH PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS INHIBITION; MOUSE; MTDH GENE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL GROWTH; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; NUDE MOUSE; PROGNOSIS; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL ADHESION MOLECULES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920493413     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.050     Document Type: Article

References (37)

1. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838.
2. Zhang N., Wang X., Huo Q., Sun M., Cai C., Liu Z., et al. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene 2014, 33(24):3119-3128.
3. Buffa F.M., Camps C., Winchester L., Snell C.E., Gee H.E., Sheldon H., et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011, 71(17):5635-5645.
4. Mulrane L., McGee S.F., Gallagher W.M., O'Connor D.P. miRNA dysregulation in breast cancer. Cancer Res 2013, 73(22):6554-6562.
5. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol 2008, 26(8):1275-1281.
6. Bisso A., Faleschini M., Zampa F., Capaci V., De Santa J., Santarpia L., et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013, 12(11):1679-1687.
7. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med 2010, 363(20):1938-1948.
8. Kasinski A.L., Slack F.J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11(12):849-864.
9. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451(7175):147-152.
10. Wang L., Wang J. MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene 2012, 31(20):2499-2511.
11. Su Z.Z., Kang D.C., Chen Y., Pekarskaya O., Chao W., Volsky D.J., et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 2002, 21(22):3592-3602.
12. Yu C., Liu Y., Tan H., Li G., Su Z., Ren S., et al. Metadherin regulates metastasis of squamous cell carcinoma of the head and neck via AKT signalling pathway-mediated epithelial-mesenchymal transition. Cancer Lett 2014, 343(2):258-267.
13. Kochanek D.M., Wells D.G. CPEB1 regulates the expression of MTDH/AEG-1 and glioblastoma cell migration. Mol. Cancer Res 2013, 11(2):149-160.
14. Huang S., Wu B., Li D., Zhou W., Deng G., Zhang K., et al. Knockdown of astrocyte elevated gene-1 inhibits tumor growth and modifies microRNAs expression profiles in human colorectal cancer cells. Biochem. Biophys. Res. Commun 2014, 444(3):338-345.
15. Sarkar D. AEG-1/MTDH/LYRIC in liver cancer. Adv. Cancer Res 2013, 120:193-221.
16. Yao Y., Gu X., Liu H., Wu G., Yuan D., Yang X., et al. Metadherin regulates proliferation and metastasis via actin cytoskeletal remodelling in non-small cell lung cancer. Br. J. Cancer 2014, 111:355-364.
17. Xu C., Kong X., Wang H., Zhang N., Kong X., Ding X., et al. MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells. Cell. Physiol. Biochem 2014, 33(5):1557-1567.
18. Gao J., Li L., Wu M., Liu M., Xie X., Guo J., et al. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS ONE 2013, 8(6):e65138.
19. Jansen M.P., Reijm E.A., Sieuwerts A.M., Ruigrok-Ritstier K., Look M.P., Rodriguez-Gonzalez F.G., et al. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res. Treat 2012, 133(3):937-947.
20. Zhang B., Liu X.X., He J.R., Zhou C.X., Guo M., He M., et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 2011, 32(1):2-9.
21. Deng M., Tang H.L., Lu X.H., Liu M.Y., Lu X.M., Gu Y.X., et al. miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS ONE 2013, 8(8):e72662.
22. Tang H., Deng M., Tang Y., Xie X., Guo J., Kong Y., et al. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. Clin. Cancer Res 2013, 19(20):5602-5612.
23. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527.
24. Gao J., Liu Q.G. The role of miR-26 in tumors and normal tissues (Review). Oncol. Lett 2011, 2(6):1019-1023.
25. Ji J., Shi J., Budhu A., Yu Z., Forgues M., Roessler S., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med 2009, 361(15):1437-1447.
26. Jiang D.S., Wang Y.W., Jiang J., Li S.M., Liang S.Z., Fang H.Y. MicroRNA-26a involved in Toll-like receptor 9mediated lung cancer growth and migration. Int. J. Mol. Med 2014, 34(1):307-312.
27. Li L., Xie X., Luo J., Liu M., Xi S., Guo J., et al. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol. Ther 2012, 20(12):2326-2334.
28. Li L., Yuan L., Luo J., Gao J., Guo J., Xie X. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin. Exp. Med 2012, 13:109-117.
29. Lu J., He M.L., Wang L., Chen Y., Liu X., Dong Q., et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011, 71(1):225-233.
30. Chen B., Liu Y., Jin X., Lu W., Liu J., Xia Z., et al. MicroRNA-26a regulates glucose metabolism by direct targeting PDHX in colorectal cancer cells. BMC Cancer 2014, 14:443.
31. Zhu Y., Lu Y., Zhang Q., Liu J.J., Li T.J., Yang J.R., et al. MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 2012, 40(10):4615-4625.
32. Huse J.T., Brennan C., Hambardzumyan D., Wee B., Pena J., Rouhanifard S.H., et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009, 23(11):1327-1337.
33. Tan S., Ding K., Li R., Zhang W., Li G., Kong X., et al. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2. Breast Cancer Res 2014, 16(2):R40.
34. Kang D.C., Su Z.Z., Sarkar D., Emdad L., Volsky D.J., Fisher P.B. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 2005, 353(1):8-15.
35. Tokunaga E., Nakashima Y., Yamashita N., Hisamatsu Y., Okada S., Akiyoshi S., et al. Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer. Breast Cancer 2014, 21(3):341-349.
36. Li X., Kong X., Huo Q., Guo H., Yan S., Yuan C., et al. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition. Cancer Sci 2011, 102(6):1151-1157.
37. Zhu K., Dai Z., Pan Q., Wang Z., Yang G.H., Yu L., et al. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin. Cancer Res 2011, 17(23):7294-7302.